| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Quarterly results |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/25/2023 |
8-K
| Quarterly results |
| 05/18/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/04/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Placement Agency Agreement, between ContraFect Corporation and Maxim Group LLC",
"Form of Pre-Funded Common Stock Purchase Warrant",
"Form of Common Stock Purchase Warrant",
"Opinion of Latham & Watkins LLP",
"Securities Purchase Agreement, by and between ContraFect Corporation and the Purchaser",
"ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement YONKERS, N.Y., Feb 28, 2023 — ContraFect Corporation , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents , including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10.0 million of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock and associated warrants will be $4.00. Under the terms..." |
|
| 03/02/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/14/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles o... |
| 02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in ContraFect Corporation |
| 02/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 02/02/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 01/31/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 01/03/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 12/22/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/25/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/09/2022 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 4.1% stake in CONTRAFECT CORPORATION |
| 08/31/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/16/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results |
| 07/19/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|